3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
5
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Interventions
aldesleukin
15
Cyclophosphamide
15
fludarabine phosphate
12
fludarabine
11
Interleukin-2
10
Nivolumab
6
Ipilimumab
6
Temozolomide
5
pembrolizumab
3
Fluorouracil
3
trametinib
2
sonidegib
2
dabrafenib
2
binimetinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Sodium Chloride
2
Sirolimus
2
Radiotherapy
2
Radiation
2
Peptides
2
HhAntag691
2
Gefitinib
2
Dacarbazine
2
Cyclosporine
2
Cetuximab
2
Capecitabine
2
veliparib
1
varlilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Skin Neoplasms
×
bempegaldesleukin
×
Clear all
NCT04410445
2023-04-21
PIVOT-12
Nektar Therapeutics
Phase 3
Terminated
765 enrolled
13 charts